Gilead Sciences, Inc. (NASDAQ:GILD) Stock Holdings Trimmed by Griffith & Werner Inc.

Griffith & Werner Inc. lowered its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,832 shares of the biopharmaceutical company’s stock after selling 604 shares during the period. Gilead Sciences makes up 1.0% of Griffith & Werner Inc.’s holdings, making the stock its 29th largest position. Griffith & Werner Inc.’s holdings in Gilead Sciences were worth $1,550,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in GILD. Norges Bank bought a new stake in shares of Gilead Sciences in the 4th quarter worth $1,789,254,000. FMR LLC raised its stake in shares of Gilead Sciences by 21.6% in the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company’s stock worth $3,724,306,000 after buying an additional 7,157,113 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Gilead Sciences by 13,891.1% in the 1st quarter. GAMMA Investing LLC now owns 2,550,298 shares of the biopharmaceutical company’s stock worth $285,761,000 after buying an additional 2,532,070 shares in the last quarter. Northern Trust Corp raised its stake in shares of Gilead Sciences by 19.7% in the 4th quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company’s stock worth $1,377,707,000 after buying an additional 2,458,954 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Gilead Sciences in the 4th quarter worth $207,340,000. Institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $99.82, for a total value of $249,550.00. Following the completion of the sale, the chief financial officer now owns 165,674 shares of the company’s stock, valued at $16,537,578.68. The trade was a 1.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction dated Friday, May 30th. The stock was sold at an average price of $110.42, for a total value of $1,104,200.00. Following the completion of the sale, the chief executive officer now directly owns 620,268 shares of the company’s stock, valued at $68,489,992.56. This represents a 1.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 60,929 shares of company stock worth $6,748,980 over the last 90 days. 0.27% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on GILD shares. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. BMO Capital Markets lifted their target price on Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a report on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a “hold” rating to a “buy” rating and lifted their target price for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. Cantor Fitzgerald started coverage on Gilead Sciences in a report on Tuesday, April 22nd. They issued an “overweight” rating and a $125.00 target price on the stock. Finally, Royal Bank of Canada lifted their target price on Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a report on Wednesday, February 12th. Nine analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $110.55.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD opened at $112.46 on Friday. The business’s 50-day moving average price is $105.39 and its two-hundred day moving average price is $101.56. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. Gilead Sciences, Inc. has a one year low of $62.69 and a one year high of $119.96. The company has a market capitalization of $139.89 billion, a P/E ratio of 303.95, a price-to-earnings-growth ratio of 0.71 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating analysts’ consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The firm had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. During the same quarter in the previous year, the company posted ($1.32) earnings per share. The business’s quarterly revenue was down .3% compared to the same quarter last year. Analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be paid a $0.79 dividend. The ex-dividend date is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a yield of 2.81%. Gilead Sciences’s dividend payout ratio (DPR) is currently 66.53%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.